WHO São Tomé and Príncipe Newsletter for the 2nd Quarter - April to June 2026 - WHO | Regional Office for Africa

It’s Fall Semester, and we’re back! What an exciting time for students, faculty, and staff. As we return to the hustle and bustle amid chilly mornings and a landscape of glorious gold and crimson leaves, it’s the perfect time to reflect on the spring and summer accomplishments of the College of Veterinary Medicine’s Public Health community. Dr. Allick continued to build connections across teaching, research, mentorship, and community engagement for the Washington State University (WSU) Public Health Program. Two undergraduates engaged actively in research, including a former Public Health 101 student Riley Sharp (now an undergraduate researcher collaborating with Dr. Allick) who developed a project on college students’ knowledge and perceptions of dementia and aging, and another, Leah Grier, who explored disability access while completing a summer internship at Seattle Children’s.

Continuous glucose monitors (CGMs) could transform diabetes management for millions of Americans with type 2 diabetes who don't take insulin, according to findings published in the New England Journal of Medicine. The clinical trial found that adults using CGMs spent approximately five additional hours each day within their target blood sugar range compared with those receiving routine care. Nearly twice as many CGM users also achieved an A1c level below 7%, a common treatment goal for people with diabetes.

Patients who wore noise-canceling headphones during minimally invasive gynecological surgery were significantly less likely to experience postoperative nausea and vomiting (PONV), suggest findings from a randomized clinical trial presented at the Anesthesiology 2026 annual meeting.

“Beyond Detecting Cancer Recurrence: Can Whole-Genome Sequencing-Based ctDNA Monitoring Help Personalize Adjuvant Treatment? An exciting new study published in The Oncologist highlights the clinical potential of Signatera Genome, a whole-genome sequencing (WGS)-based, tumor-informed circulating tumor DNA (ctDNA) assay, not only for detecting molecular residual disease (MRD), but also for potentially informing adjuvant treatment decisions.